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1. Introduction 
Mycotoxins are pharmacologically active mold metabolites produced in a strain-specific 
way that elicit some complicated toxicological activities [1]. More than 300 secondary 
metabolites have been identified while only around 30 have true toxic properties [2]. The 
chemical structures of mycotoxins vary significantly, but they are low molecular mass 
organic compounds [3]. Mycotoxins are small and quite stable molecules which are 
extremely difficult to remove and enter the food and feed chain while keeping their toxic 
properties [4]. So, the occurrence of mycotoxins is regulated by legal limits in all developed 
countries [5]. Mycotoxin contamination of the feed and food is a global problem because 
more than 25% of world grain production is contaminated by mycotoxins [6]. The synthesis 
of mycotoxins by moulds is genetically determined and closely related to primary metabolic 
pathways, such as amino acid and fatty acid metabolism. However, the actual toxin 
production is modulated by environmental factors such as substrate composition and 
quality, humidity and temperature. The occurrence of mycotoxins in animal feed exhibits a 
geographic pattern, for example Aspergillus species meet optimal conditions only in tropical 
and subtropical regions, whereas Fusarium and Penicillium species are adapted to the 
moderate climate. Worldwide trade with food and feed commodities results in a wide 
distribution of contaminated material [7].  
Plant selections for mycotoxin resistance have not created any significant results in 
protection against grain mycotoxins. The major problem comes from the fact that there are 
no safe levels of mycotoxins, because of synergistic interactions of many mycotoxins [2]. 
There is sufficient evidence from animal models and human epidemiological data to 
conclude that mycotoxins cause an important hazard to human and animal health [1]. The 
toxic effect of mycotoxins on animal and human health depends on the type of mycotoxin; 
level and duration of the exposure; age, health, and sex of the exposed individual, genetics, 
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dietary status, and interactions with other toxic insults. Thus, the severity of mycotoxin 
toxicity can be complicated by factors such as vitamin deficiency, caloric deprivation, 
alcohol abuse, and infectious disease [1,3,8]. 
Mycotoxins according to their chemical structure exert a broad variety of biological effects. 
The nature and intensity of these effects depend on the actual concentration of an individual 
mycotoxin and the time of exposure [7]. Cell proliferation of all mycotoxin treated blood 
mononuclear cells was significantly decreased at the highest concentrations of mycotoxins, 
but this decrease was significantly stronger for different mixtures of mycotoxins [9]. In 
addition, feed commodities are often contaminated with more than one mycotoxin, as 
mould species produce different mycotoxins at the same time. These co-occurring 
mycotoxins can exert additive effects, as for example various trichothecenes, but may also 
act antagonistically, as for example, observed with feeds containing trichothecenes and 
zearalenone, and commodities, containing aflatoxins and cyclopiazonic acid [7]. 
Mycotoxicoses are more common in underdeveloped countries and often remain 
unrecognized by medical professionals, except when huge numbers of people are involved 
[3]. In general, mycotoxin exposure is more likely to occur in parts of the world where poor 
methods of food handling and storage are common, where malnutrition is a problem, and 
where few regulations exist to protect exposed populations. The incidence of liver cancer 
varies widely from country to country, but it is one of the most common cancers in China, 
Philippines, Thailand, and many African countries. Worldwide, liver cancer incidence rates 
are 2 to 10 times higher in developing countries than in developed countries [10]. The 
occurrence of fumonisin B1 was correlated with the occurrence of a higher incidence of 
esophageal cancer in regions of Transkei (South Africa), China, and Northeast Italy [3]. In 
Africa and Asia where the occurrence of mycotoxins is common and a high percentage of 
the population is infected with hepatitis B or C mycotoxin reduction is obligatory [8]. One of 
the strategies for reducing the exposure to mycotoxins is to decrease their bioavailability by 
including various mycotoxins-adsorbing agents in the compound feed, which lead to 
reduction of mycotoxins uptake as well as distribution to the blood and target organs. 
Another strategy is the degradation of mycotoxins into non-toxic metabolites by using 
biotransforming agents such as bacteria/fungi or enzymes [4]. 
Diagnosis of animal mycotoxicosis is based on experimental studies with specific toxins and 
specific animals, very often under well-defined toxicological laboratory conditions, so that 
the results of such studies can be far from real-life or natural situations. Furthermore, factors 
such as breeding, sex, environment, nutritional status, as well as other toxic entities can 
affect the symptoms of intoxication and may contribute to the significance of mycotoxin 
damage on economic output and animal health [11]. The economic costs of mycotoxins are 
impossible to determine accurately [12], but the US Food and Drug Administration (FDA) 
estimated that in the US the mean economic annual cost of crop losses from the mycotoxins 
aflatoxins, fumonisins, and deoxynivalenol are $932million USD [13]. While mycotoxin 
associated losses in industrial countries are typically market losses as a result of rejected 
crops, developing countries suffer additionally from health impacts [14]. Diagnosis is very 
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much dependent on receiving a sample of feed that was ingested prior to intoxication, but 
also on data from another representative group of animals of the facility and the results of a 
post-mortem examination [11, 13]. 
In the following table, the mycotoxins of major concern as feed contaminants are aflatoxins, 
ochratoxin A, Fusarium toxins (trichothecenes like, deoxynivalenol, diacetoxyscipenol, 
nivalenol, T2-toxin/HT2-toxin, zearalenone and fumonisins) [4]. Moreover, the most 
predominant mycotoxigenic species in wheat grain were A. flavus with the ability to produce 
mycotoxins (aflatoxins B1, B2, G1 and G2 and sterigmatocystin) [15].  
 
Fungal species Mycotoxin 
Aspergillus flavus; A. parasiticus Aflatoxins 
A. flavus Cyclopiazonic acid 
A. ochraceus; Penicillium viridicatum; P. cyclopium;  Ochatoxin A 
P. expansum Patulin 
Fusarium culmorum; F. graminearum; F. sporotrichioides Deoxynivalenol 
F. sporotrichioides; F. poae T-2 toxin 
F. sporotrichioides; F. graminearum; F. poae Diacetoxyscirpenol 
F. culmorum; F. graminearum; F. sporotrichioides Zearalenone 
F. moniliforme Fumonisins 
Acremonium coenophialum Ergopeptine alkaloids 
Table 1. The major toxigenic species of fungi and their mycotoxins [16] 
2. Route of mycotoxins exposure 
The most common route of exposure to mycotoxins is ingestion, but it may also involve 
dermal, respiratory, and parenteral routes, the last being associated with drug abuse [17]. In 
general, animals are directly exposed to mycotoxins through the consumption of mouldy 
feedstuffs, eating contaminated foods, skin contact with mould infected substrates and 
inhalation of spore-borne toxins [1]. Human exposure can be via one of two routes; direct 
exposure due to the consumption of mouldy plant products, or indirect exposure through 
the consumption of contaminated animal products containing residual amounts of the 
mycotoxin ingested by the food producing animals [18]. Human exposure to mycotoxins is 
further determined by environmental or biological monitoring. In environmental 
monitoring, mycotoxins are measured in food, air, or other samples; in biological 
monitoring, the presence of residues, adducts, and metabolites is assayed directly in tissues, 
fluids, and excretory products [19]. The risk of systemic toxicity resulting from dermal 
exposure increases in the presence of high toxin concentrations, occlusion, and vehicles 
which enhance penetration [20]. The main human and veterinary health load of mycotoxin 
exposure is related to chronic exposure [2]. 
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3. Mycotoxins metabolism and induction of oxidative stress 
Biodegradation of mycotoxins with microorganisms or enzymes is considered as the best 
strategy for detoxification of feedstuffs. This approach is considered as environmental 
friendly approach in contrast to physicochemical techniques of detoxification. Ruminants 
are potential source of microbes or enzymes for mycotoxins biodegradation [21]. In 
vertebrate, mycotoxin is metabolized by cytochrome P450 enzymes to metabolite-guanine-
N7 adduct (Fig 1). The carcinogenic potency is highly correlated with the extent of total 
DNA adducts formed in vivo [22].  
 
Figure 1. Mycotoxin metabolism in vertebrates [23] 
Cytotoxicity and ROS generation are mechanisms of mycotoxins mediated toxicity. ROS are 
chemically reactive molecules containing oxygen. They are highly reactive due to the 
presence of unpaired electrons. ROS formed as a natural byproduct of the normal 
metabolism of oxygen have important roles in cell signaling and homeostasis. However, 
during times of environmental stress, ROS levels can increase dramatically as a result of 
oxidative stress [24]. Oxidative stress occurs when the concentration of ROS generated 
exceeds the antioxidant capability of the cell. In other words, oxidative stress describes 
various deleterious processes resulting from an imbalance between the excessive formation 
of ROS and limited antioxidant defenses [25]. Under normal conditions, ROS are cleared 
from the cell by the action of superoxide dismutase (SOD), catalase (CAT), or glutathione 
peroxidase (GPx). The main damage to cells results from the ROS-induced alteration of 
macromolecules such as polyunsaturated fatty acids in membrane lipids, proteins, and 
DNA. Additionally, oxidative stress and ROS can originate from xenobiotic bioactivation by 
prostaglandin H synthase (PHS) and lipoxygenases (LPOs) or microsomal P450s which can 
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oxidize xenobiotics to free radical intermediates that react directly or indirectly with oxygen 
to produce ROS and oxidative stress [26] as in Fig (2). Moreover, the cell can tolerate a small 
to moderate amount of oxidative stress by producing antioxidant molecules e.g vitamin A, 
C &E and GSH and activates enzymes e.g. CAT, SOD, GPx, glutathione reductase (GR) and 
glutathione S transferase (GST) to counteract the excess oxidants [27]. LPO may bring about 
protein damage and inactivation of membrane-bound enzyme either through direct attack 
by free radicals or through chemical modification by its end products [28]. Reduction of 
cellular viability by mycotoxins was correlated with increases of ROS generation and MDA 
formation in concentration and time dependent manner [29]. The importance of oxidative 
stress and LPO in mycotoxins toxicity was confirmed by the protective effects of natural 
antioxidants [2]. Sporidesmin, the mycotoxin responsible for ‘facial eczema’ in ruminants, 
contains a disulphide group which appears to be intimately involved in its toxic action. The 
dithiol form of sporidesmin has been shown readily to undergo autoxidation in vitro in a 
reaction which generates superoxide radical (O2−) [30]. GST found in the cytosol and 
microsomes catalyzes the conjugation of activated aflatoxins with GSH, leading to the 
excretion of aflatoxin [31]. Variations in the level of the GST as well as variations in the 
cytochrome P450 system are thought to contribute to the differences observed in 
interspecies aflatoxin susceptibility [22, 32]. 
 
Figure 2. General pathways of ROS production and clearance [26] 
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4. Mycotoxin toxicity 
The amount of mycotoxins needed to produce adverse health effects varies widely among 
toxins, as well as for each animal or person’s immune system. Two concepts are needed to 
understand the negative effects of mycotoxins on human health: Acute toxicity, the rapid 
onset of an adverse effect from a single exposure. Chronic toxicity, the slow or delayed onset 
of an adverse effect, usually from multiple, long-term exposures. Mycotoxins can be acutely 
or chronically toxic, or both, depending on the kind of toxin and the dose. Membrane-active 
properties of various mycotoxins determine their toxicity. Incorporation of mycotoxins into 
membrane structures lead to alterations in membrane functions. In general, mycotoxins 
effects on DNA, RNA, protein synthesis and the pro-apoptotic action (Fig. 3) causing 
changes in physiological functions including growth, development and reproduction [2]. 
Clinicians often arrange mycotoxins by the organ they affect. Thus, mycotoxins can be 
classified as hepatotoxins, nephrotoxins, neurotoxins, immunotoxins, and so forth. Cell 
biologists put them into generic groups such as teratogens, mutagens, carcinogens, and 
allergens [1]. 
 
Figure 3. Mycotoxins affecting major sites in RNA and protein synthesis [33]  
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Aflatoxins 
Aflatoxins occur in nuts, cereals and rice under conditions of high humidity and 
temperature. The two major Aspergillus species that produce aflatoxins are A. flavus, which 
produces only B aflatoxins, and A. parasiticus, which produces both B and G aflatoxins. 
Aflatoxins M1 and M2 are oxidative metabolic products of aflatoxins B1 and B2 produced by 
animals following ingestion, and so appear in milk, urine and faeces. Aflatoxicol is a 
reductive metabolite of aflatoxin B1. Aflatoxins are acutely toxic, immunosuppressive, 
mutagenic, teratogenic and carcinogenic compounds (classified as group 1 carcinogens 
according to the International Agency for Research on Cancer (IARC) [34]. Aflatoxins have 
been detected in the blood of pregnant women, in neonatal umbilical cord blood, and in 
breast milk in African countries, with significant seasonal variations [35]. The geographical 
and seasonal occurrence of aflatoxins in food and of kwashiorkor shows a remarkable 
similarity [36]. It has been hypothesized that kwashiorkor, a severe malnutrition disease, 
may be a form of pediatric aflatoxicosis [37]. Aflatoxins exposure accounts for about 40% of 
the load of disease in developing countries where a short lifespan is prevalent. Food systems 
and economics in developed country make the advance in aflatoxins management 
impossible [38]. The prevention of mycotoxins toxicity involves reduction of mycotoxin 
levels in foodstuffs and increasing the intake of diet components such as vitamins, 
antioxidants and substances known to prevent carcinogenesis [39]. The prevention of 
mycotoxin contamination of human foods could have a significant effect on public health in 
low-income countries due to enhanced food safety [40]. Chemoprotection against aflatoxins 
has been confirmed with the use of a number of compounds that either increase an animal’s 
detoxification processes [41] or prevent the production of the epoxide that leads to 
cytotoxicity [42]. For the animal feed industries, a major focus has been on developing food 
additives that provide protection from the mycotoxins. One approach has been the use of 
esterified glucomanoses and other yeast extracts that provide chemoprotection by increasing 
the detoxification of aflatoxin [41]. 
 
Figure 4. Metabolism of aflatoxin in liver [46] 
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After the absorption, highest concentration of the toxin is found in the liver [43]. Once in 
liver, aflatoxin B1 is metabolized by microsomal enzymes cytochrome P-450 3A4 to different 
metabolites through hydroxylation, hydration, demethylation and epoxidation. Variations 
in its catalytic activity of P-450 3A4 are important in issues of bioavailability and drug-drug 
interactions [44]. As in Fig (4) the hydroxylation of AFB1 at C4 or C22 produces, AFM1 and 
AFQ1, respectively. Hydration of the C2 – C3 double bond results in the formation of AFB2a 
which is rapidly formed in certain avian species [45]. AFP1 results from o-demethylation 
while the AFB1 – epoxide is formed by epoxidation at the 2,3 double bond Aflatoxicol is the 
only metabolite of AFB1 produced by a soluble cytoplasmic reductase enzyme system [46] . 
The putative AFB1 epoxide is generally accepted as the active electrophilic form of AFB1 
that may attack nucleophilic nitrogen, oxygen and sulphur heteroatoms in cellular 
constituents [47]. This highly reactive substance may combine with DNA bases such as 
guanine to produce alterations in DNA [36]. However, both humans and animals possess 
enzymes system, which are capable of reducing the damage to DNA and other cellular 
constituents caused by the 8,9-epoxide. For example GST mediates the conjugation reaction 
of the 8,9-epoxide to the endogenous compound GSH, this essentially neutralizes its toxic 
potential (Fig. 5). Animal species such as the mouse that are resistant to aflatoxin 
carcinogenesis have 3-5 times more GST activity than susceptible species such as the rat. 
Humans have less GST activity or 8,9-epoxide conjugation than rats or mice suggesting that 
humans are less capable of detoxifying this important metabolite [48]. 
 
Figure 5. Biomarkers of aflatoxin exposure in an internal dose and a biologically effective dose. 
Biomarkers of exposure include aflatoxin M1, the internal dose includes the aflatoxin-mercapturic acid 
and aflatoxinalbumin adduct, and the biologically effective dose is reflected by the excretion of the 
aflatoxin-N7-guanine adduct formed by depurination leading to an apurinic (AP) site in DNA [49]. 
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The diseases caused by aflatoxin consumption are called aflatoxicosis. Acute aflatoxicosis 
results in death, however, chronic aflatoxicosis results in immune suppression and cancer 
[19]. Suppression of the cell-mediated immune response was mediated by altered cytokine 
expression [50]. Aflatoxins caused hepatotoxicity, nephrotoxicity and genotoxicity in 
somatic and germ cells, resulted in mitotic and meiotic delay in mice [51]. An increase in 
AFB1-8, 9-epoxide cause a significant increases in hepatic LPO level [52]. Peroxidation of 
membrane lipids initiated loss of membrane integrity; membrane bound enzyme activity 
and cell lysis [53]. LPO was significantly increased in the liver, kidney [54] and testis [55] of 
aflatoxin-treated mice as compared to controls. However, GSH levels declined significantly 
in the liver, kidney and testis after 45 days of aflatoxin treatment [56]. Moreover, AFB1 
intake and expression of enzymes involved in AFB1 activation/detoxification may play an 
important role in hepatitis B virus-related hepatocarcinogenesis [57]. The results of a clinical 
trial suggest that chlorophyllin may have a role in preventing dietary exposure to aflatoxin 
B1 by reducing its oral bioavailability [58]. 
Srategies for reducing exposure and risk from aflatoxin in developing countries should be 
carefully tested and validated using clinical trial designs with biomarkers serving as 
objective endpoints. Clinical trials and other interventions are designed to translate findings 
from human and experimental investigations to public health prevention. Both primary (to 
reduce exposure) and secondary (to alter metabolism and deposition) interventions can use 
specific biomarkers as endpoints of efficacy. In a primary prevention trial, the goal is to 
reduce exposure to aflatoxins in the diet. A range of interventions includes planting pest-
resistant varieties of staple crops, attempting to lower mould growth in harvested crops, 
improving storage methods following harvest, and using trapping agents that block the 
uptake of unavoidably ingested aflatoxins. In secondary prevention trials, one goal is to 
modulate the metabolism of ingested aflatoxin to enhance detoxification processes, thereby 
reducing internal dose and subsequent risk [49] (Fig. 6).  
Ochratoxin A (OTA) 
Ochratoxins are the first major group of mycotoxins identified after the discovery of the 
aflatoxins [59]. OTA is found in a variety of plant food products such as cereals. Because of 
its long half life, it accumulates in the food chain [60]. OTA is absorbed passively 
throughout the gastrointestinal tract and actively in the kidneys. Highest amounts of OTA 
could be found in the blood and it is distributed in kidney, liver, muscle and adipose tissue 
in a decreasing order. The toxin is excreted primarily in the urine, and to a lesser degree in 
bile and also in milk. The half-life of experimentally orally ingested OTA is shorter than 
intravenously injected OTA [61]. According to IRAC [34] OTA is classified as group 1 
carcinogens. Structure-activity studies suggested that the toxicity of OTA may be attributed 
to its isocoumarin moiety and lactone carbonyl group. OTA reduces the expression of 
several genes regulated by nuclear factor-erythroid 2 p45-related factor (Nrf2) and reduces 
the expression of antioxidant enzymes through inhibition of Nrf2 [62, 63]. OTA toxicity may 
be involved in the development of certain kidney diseases through generation of oxidative 
stress [64]. Chronic administration of low dose of OTA caused morphological and functional 
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changes in proximal tubules and administration of date extract protects against OTA-
induced tubule’s tissue damage [65]. However, antioxidant treatment failed to prevent the 
development of OTA-induced tumors in animal models [66]. Indomethacin and aspirin 
were found to prevent OTA genotoxicity in the urinary bladder and kidney of mice [67]. 
OTA causes acute depletion of striatal dopamine and its metabolites, accompanying 
evidence of neural cell apoptosis in the substantia nigra, stratum and hippocampus [68].  
 
Figure 6. Strategies for reducing exposure and risk from aflatoxin in developing countries [49] 
OTA has complex mechanisms of action that include oxidative stress, bio-energetic 
compromise, mitochondrial impairment, inhibition of protein synthesis, production of DNA 
single strand breaks and formation of OTA-DNA adducts [69-71]. OTA induced renal 
toxicity and carcinogenicity may be mediated by an Nrf2-dependent signal transduction 
pathway [63]. It is a mitochondrial poison causing mitochondrial damage, oxidative burst, 
LPO and interferes with oxidative phosphorylation [72, 73]. OTA was found to chelate ferric 
ions (Fe3 ), facilitating their reduction to ferrous ions (Fe2
 
), which in the presence of oxygen, 
provided the active species initiating LPO [74]. OTA hydroquinone/ quinone couple was 
generated from the oxidation of OTA by electrochemical, photochemical and chemical 
processes resulting in redox cycling and in the generation of ROS [75]. OTA impairs the 
antioxidant defense of the cells making them more susceptible to oxidative damage [62] and 
a reduction in cellular antioxidant defense may contribute to the production of OTA-
dependent oxidative damage [76]. 
Studies carried out in several countries including Tunisia, Egypt and France, have indicated 
a link between dietary intake of OTA and the development of renal and urothelial tumours 
[77- 81]. OTA is known to affect the immune system in a number of mammalian species. The 
type of immune suppression experienced appears to be dependant on a number of factors, 
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including the species involved, the route of administration, the doses tested, and the 
methods used to detect the effects [82]. OTA causes immunosuppression following prenatal, 
postnatal and adult-life exposures. These effects include reduced phagocytosis and 
lymphocyte markers [83] and increased susceptibility to bacterial infections and delayed 
response to immunization in piglets [9]. OTA induces apoptosis in a variety of cell types in 
vivo and in vitro that mediated through cellular processes involved in the degradation of 
DNA [84]. Moreover, the immunosuppressant activity of OTA is characterized by size 
reduction of vital immune organs, such as thymus, spleen, and lymph nodes, depression of 
antibody responses, alterations in the number and functions of immune cells, and 
modulation of cytokine production (TNF-α and Il-6). The immunotoxic activity of OTA 
probably results from degenerative changes and cell death following necrosis and apoptosis, 
in combination with slow replacement of affected immune cells, due to inhibition of protein 
synthesis [85]. Finally, it is proposed that a network of interacting epigenetic mechanisms, 
including protein synthesis inhibition, oxidative stress and the activation of specific cell 
signalling pathways is responsible for OTA carcinogenicity [86] (Fig.7)  
 
Figure 7. Scheme to illustrate the oxidative stress-mediated mode of action proposed for OTA. 
Increased production of ROS, RNS, and RCS is likely to originate either from direct redox reactions 
involving OTA or through the inhibition of cellular defenses such as through the inhibition of 
transcription factors as Nrf2 which regulates enzymes with antioxidant properties. The generation of 
radicals will induce macromolecular oxidative damage such as oxidized DNA bases which may be 
converted into mutation resulting into generation of transformed cells [66]. 
Trichothecenes 
Trichothecenes (TCs) are mycotoxins produced mostly by members of the Fusarium genus 
and other genera (e.g. Trichoderma, Trichothecium, Myrothecium and Stachybotrys). By now, 
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more than 180 different trichothecenes and trichothecene derivatives have been isolated and 
characterized [87, 88]. TCs were found in air samples collected during the drying and 
milling process on farms, in the ventilation systems of private houses and office buildings 
and on the walls of houses with high humidity [89-90]. They can be divided into four 
categories according to both their chemical properties and their producer fungi; 
1. Type A: functional group other than a ketone at C8 position (e.g.; T-2, HT-2, DAS); 
2. Type B: carbonyl functions at C8 position (e.g.; DON, NIV, FUS-X, 3-acetyl-
deoxynivalenol, 15-acetyl-deoxynivalenol); 
3. Type C: second epoxide group at C7, 8 or C9, 10; (e.g.; crotocin and baccharin); 
4. Type D: macrocyclic ring system between C4 and C15 with two ester linkages (e.g.; 
satratoxin G, H, roridin A and verrucarin A) [87, 91, 92]. 
TCs exposure leads to apoptosis both in vitro and in vivo in several organs such as lymphoid 
organs, hematopoietic tissues, liver, intestinal crypts, bone marrow and thymus [91, 93]. 
Acute high dose toxicity of TCs is characterized by diarrhea, vomiting, leukocytosis, 
haemorrhage, and circulatory shock and death, whereas chronic low dose toxicity is 
characterized by anorexia, reduced weight gain, neuroendocrine and immunologic changes 
[91, 94]. The myelotoxicity was considered highest for T-2 and HT-2 toxins and lowest for 
DON and NIV [94]. TCs are toxic to many animal species, but the sensitivity varies 
considerably between species and also between the different TCs [93]. Cellular effects on 
DNA and membrane integrity have been considered as secondary effects of the inhibited 
protein synthesis. The toxin binds to the peptidyl transferase, which is an integral part of the 
60S ribosomal subunit of mammalian ribosome. TCs interfere with the metabolism of 
membrane phospholipids and increase liver LPO in vivo. Also, some TCs are shown to 
change the serotonin activity in the central nervous system, which is known to be related in 
the regulation of food intake [88].  
T-2 Toxin 
T-2 toxin is a cytotoxic secondary fungal metabolite that belongs to TCs family produced by 
various species of Fusarium (F. sporotichioides, F. poae, F. equiseti, and F. acuminatum), which 
can infect corn, wheat, barley and rice crops in the field or during storage [95]. T-2 toxin is a 
well known inhibitor of protein synthesis through its high binding affinity to peptidyl 
transferase resulting in trigger of ribotoxic stress response that activate mitogen-activated 
protein kinases [96]. Moreover, T-2 toxin interferes with the metabolism of membrane 
phospholipids and increases liver LPO [97]. Also, T-2 toxin suppresses drug metabolizing 
enzymes such as GST [98]. T-2 toxin treated mice showed a time-dependent increase in ROS 
generation, depletion of GSH, increases in LPO and protein carbonyl content in the brain. 
Moreover, the gene expression profile of antioxidant enzymes showed a significant increase 
in SOD and CAT via the dermal route and GR and GPx via the subcutaneous route [99]. 
General signs of T-2 include nausea, emesis, dizziness, chills, abdominal pain, diarrhea, 
dermal necrosis, abortion, irreversible damage to the bone marrow, reduction in white 
blood cells and inhibition of protein synthesis [100, 101]. Moreover, the effects of T-2 toxins 
on the immune system include changes in leukocyte counts, delayed hypersensitivity, 
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depletion of selective blood cell progenitors, depressed antibody formation and allograft 
rejection [39]. Also, T-2 toxin has a direct lytic effect on erythrocytes [102]. T-2 toxin can 
induce apoptosis in many types of cells bearing rapid rates of proliferation [103] and 
increased the expression of both oxidative stress and apoptosis related genes in hepatocytes 
of mice [104]. T-2 toxin induces neuronal cell apoptosis in the fetal and adult brain [68]. In 
this aspect, it suggested that dysfunction of the mitochondria and oxidative stress might be 
the main factor behind the T-2 toxin-induced apoptosis in the fetal brain [105]. ROS activate 
caspase-2 which play a crucial role in the control of apoptosis [106, 107]. Moreover, it was 
demonstrated that T-2 toxin induced cytotoxicity in HeLa cells is mediated by generation of 
ROS leading to DNA damage and trans activation of p53 protein expression which leads to 
shift in the ratio of Bax/Bcl-2 in favour of apoptosis and subsequent release of Cyt-c from 
mitochondria followed by caspase cascade [99].  
Fumonisins 
Fumonisins produced by the fungus Fusarium verticillioides, a widespread fungal 
contaminants of various cereals, predominantly corn [2, 108]. Fumonisn B1 (FB1) and B2 are 
of toxicological significance, while the others (B3, B4, A1 and A2) occur in very low 
concentrations and are less toxic [3]. FB1 is poorly absorbed and rapidly eliminated in feces. 
Minor amounts are retained in liver and kidneys. FB1 does not cross the placenta and is not 
teratogenic in vivo in rats, mice, or rabbits, but is embryotoxic at high, maternally toxic doses 
[109]. FB1 has been linked to a number of diseases in humans and animals [1, 40]. FB1 
increases oxidative DNA damage, as measured by increased DNA strand breaks and 
malondialdehyde adducts in rat liver and kidney in vivo [111]. As shown in Fig. (9) an 
alternative mechanism of action of FB1 involves the disruption of the de novo sphingolipid 
biosynthesis pathway by inhibition of the enzyme ceramide synthase [68, 112]. The 
inhibition of sphingolipid biosynthesis disrupts numerous cell functions and signaling 
pathways, including apoptosis and mitosis, thus potentially contributing to carcinogenesis 
through an altered balance of cell death and replication [113]. Disruption of sphingolipid 
metabolism leads to changes in the sphinganine to sphingosine ratio [114] as demonstrated 
in rat liver and mouse kidney at carcinogenic doses of FB1 [115]. 
FB1-induced DNA damage and hepatocarcinogenesis in experimental models can be 
modulated by a variety of factors including nutrients, chemopreventive agents, and 
other factors such as food restriction and viral infection, as well as genetic 
polymorphisms [118]. In rat C6 glioma cells, FB1 inhibits protein synthesis, causes DNA 
fragmentation and cell death, increases 8-hydroxy-2’-deoxyguanosine, induces LPO, and 
cell cycle arrest [119]. Also, the signs of apoptosis were increased caspase-3 like protease 
activity and internucleosomal DNA fragmentation [120]. Furthermore, the disruption of 
membrane structure, the enhancement of membrane endocytosis, and the increase in 
membrane permeability caused by FB1 in macrophages provide additional insight into 
potential mechanisms by which the fumonisins might enhance oxidative stress and 
cellular damage [121]. 
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Figure 8. Pathway of de novo synthesis (not in boxes) and turnover of sphingolipids (boxed) in animal 
cells, and their inhibition by fumonisins. Fumonisns inhibit the synthesis of ceramides by specifically 
binding to sphingosine and sphinganine [116, 117] 
Zearalenone 
Zearalenone (ZEA) is produced mainly by Fusarium graminearum and related species, 
principally in wheat and maize. ZEA and its derivatives produce estrogenic effects in 
various animal species [3]. The structure of the ZEA similar to steroids and binds to ER as an 
agonist. There are two major biotrasformation pathways for ZEA in animals (1) 
hydroxylation catalyzed by 3α- and 3β- hydroxysteroid dehydrogenase (HSDs) resulting in 
the formation of α- and β-ZOL; (2) conjugation of ZEA and its metabolites with glucuronic 
acid, catalyzed by uridine diphosphate glucuronyl transferase. Consequently, ZEA is a 
substrate for 3α-HSD and 3β-HSD present in many steroidogenic tissues, such as liver, 
kidney, testis, prostate, hypothalamus, pituitary, ovary, intestine [122, 123]. The adverse 
effects of ZEA are partly determined by the processes of elimination, because the biliary 
excretion and entero-hepatic cycling are important processes affecting the fate of ZEA and 
explaining a different sensitivity between animals [124]. α and β Zearalenol metabolites 
caused cytotoxicity by inhibiting cell viability, protein and DNA syntheses and inducing 
oxidative damage and over-expression of stress proteins. However, the ZEA metabolites 
exhibited lower toxicity than ZEA, with β zearalenol being the more active of the two 
metabolites [125]. In addition, oxidative damage is likely to be evoked as one of the main 
pathways of ZEA toxicity which may initiate event at least in part contribute to the 
mechanism of ZEA induced genotoxic and cytotoxic effects [126]. ZEA and its derivatives 
compete effectively with 17 β-E2 for the specific binding sites of the oestrogen receptors 
(ERs) occurring in different organs. Two subtypes of ER exist, ER-α and ERβ that are 
differently distributed in the body. Binding of ZEA and its derivatives initiate a sequence of 
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events known to follow estrogen stimulation of target organs [127, 128]. So, the effect of ZEA 
and its metabolites depends upon the reproductive status (prepubertal, cycling or pregnant) 
of the affect animals [123]. ZEA do not induce apoptosis in porcine ovaries [129], however, 
apoptosis is the principal mechanism contributing to germ cell depletion and testicular 
atrophy following ZEA exposure [130]. Moreover, ZEA has potent effects on the expression 
of chicken splenic lymphocytes cytokines at the mRNA level [131]. 
Patulin 
Patulin (PAT) is a toxic chemical contaminant produced by several species of mould, 
especially within Aspergillus, Penicillium and Byssochlamys. It is the most common mycotoxin 
found in apples and apple-derived products such as juice, cider, compotes and other food 
intended for young children. Exposure to this mycotoxin is associated with immunological, 
neurological and gastrointestinal outcomes [132]. PAT-induced nephropathy and 
gastrointestinal tract malfunction have been demonstrated in animal models [133]. The toxic 
effects of PAT on various cells related to its activity on SH groups [134]. Moreover, it 
suggested that PAT-induced apoptosis is mediated through the mitochondrial pathway 
without the involvement of p53 [12]. The interaction with sulfhydryl groups of 
macromolecules by PAT and the subsequent generation of ROS plays a primary role in the 
apoptotic process. The genotoxic effects might be related to its ability to react with 
sulfhydryl groups and to induce oxidative damage [135]. PAT was found to reduce the 
cytokine secretion of IFN-γ and IL-4 by human macrophages [136] and of IL-4, IL-13, IFN-γ, 
and IL-10 by human peripheral blood mononuclear cells and human T cells [137]. The 
clinical signs of PAT toxicosis are typical of the nervous syndrome. Animals present 
hyperaesthesia, lack of coordination of motor organs, problems with ingestion and 
digestion. At the molecular level, PAT alters ion permeability and/or intracellular 
communication, causing oxidative stress and cell death (116).  
Citrinin 
Citrinin is a toxic metabolite produced by several filamentous fungi of the genera 
Penicillium, Aspergillus and Monascus, which has been encountered as a natural contaminant 
in grains, foods, feedstuffs, as well as biological fluids. Some analytical systems have been 
developed for its detection and quantification [138]. As one of mycotoxins, citrinin possesses 
antibiotic, bacteriostatic, antifungal and antiprotozoal properties. While it is also known as a 
hepato-nephrotoxin in a wide range of species [139], in vitro studies have demonstrated that 
citrinin produced multiple effects on renal mitochondrial function and macromolecule 
biosynthesis that ultimately resulted in cell death [140]. Citrinin inhibited the oxygen 
consumption rate by about 45 % and inhibited the glucose utilization of BHK-21 cells by 
about 86 % due to alterations in mitochondrial function and in the glycolytic anaerobic 
pathway [141]. Citrinin occurred frequently together with another nephrotoxin–ochratoxin 
A in foodstuffs such as cereals, fruits, meat [142] and cheese [143]. Citrinin can act 
synergistically with ochratoxin A to depress RNA synthesis in murine kidneys [144, 145]. 
The simultaneous exposure of rabbits to citrinin with OTA even at sub-clinical dietary levels 
potentiated the OTA induced nephrotoxicity at ultrastructural level [146]. To avoid the 
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direct/indirect intake of citrinin, it is important to develop detoxification methods for 
citrinin during food processing. So far, there have been several reports on the detoxification 
of citrinin. The investigation on thermal decomposition and detoxification showed that, in 
the presence of a small amount of water, heating citrinin at 130oC caused a significant 
decrease in its toxicity to Hela cells [147]; whereas heating at 150oC in water caused 
formation of highly toxic compounds [148]. 
Ergot Alkaloids 
The ergot alkaloids are among the most fascinating of fungal metabolites. They are classified 
as indole alkaloids and are derived from a tetracyclic ergoline ring system [149]. These 
compounds are produced as a toxic cocktail of alkaloids in the sclerotia of species of Claviceps, 
which are common pathogens of various grass species. Ergotism is still an important 
veterinarian problem. The principal animals at risk are cattle, sheep, pigs, and chickens. 
Clinical symptoms of ergotism in animals include gangrene, abortion, convulsions, 
suppression of lactation and hypersensitivity [150]. More recently, pure ergotamine has been 
used for the treatment of migraine headaches. Other ergot derivatives are used as prolactin 
inhibitors, in the treatment of Parkinsonism, and in cases of cerebrovascular insufficiency 
[149]. The therapeutic administration of ergot alkaloids may cause sporadic cases of human 
ergotism [151]. Ergotism is extremely rare today, primarily because the normal grain cleaning 
and milling processes remove most of the ergot so that only very low levels of alkaloids 
remain in the resultant flours. In addition, the alkaloids that are the causative agents of 
ergotism are relatively labile and are usually destroyed during baking and cooking [3]. 
Satratoxin G 
Satratoxin G is one of the most potent macrocylclic TCs produced by Stachybotrys chartarum 
[152]. Roridin A is a commercially available macrocyclic TC used as a stratoxin G substitute, 
and roridin L2 is a putative biosynthetic precursor of satratoxin [153]. Satratoxin G is potent 
inhibitors of eukaryotic translation that are potentially immunosuppressive. It rapidly binds 
small and large ribosomal subunits in a concentration- and time-dependent manner that 
was consistent with induction of apoptosis [154]. A signal transduction pathway in 
satratoxin-induced apoptosis in HL-60 cells involves, caspase-3 activation through 
activation of both caspase-8 and caspase-9 along with cytosolic release of cytochrome c and 
fragmentation of nucleosomal DNA by DFF-40/CAD [155]. 
Roridin E 
Roridin E is a well-known macrocyclic trichothecene mycotoxin possessing potent anti-
proliferative activity against cancer cell lines [156]. Four new isolated from a marine-derived 
fungus, Myrothecium roridum strain 98F42 [157]. One of them, 12-deoxy derivative of roridin 
E, showed reduced cytotoxicity about 80-fold less than that of roridin E against human 
promyelocytic (HL-60) and murine leukemia (L1210) cell lines [158]. Treatment of rats with 
roridin E caused minimal toxicity on the hepatic and renal tissue, however, co 
administration of linoleic acid with roridin E resulted in increase toxicity due to increased 
incorporation to the cell membrane or inhibit its biotransformation [159]. 
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5. Mmycotoxins and apoptosis 
Apoptosis is a process for maintenance of tissue homeostasis. Several processes, such as 
initiation of death signals at the plasma membrane, expression of pro-apoptotic 
oncoproteins, activation of death proteases and endonucleases combine to cause cell 
termination. ROS may play a major role in apoptosis. GSH depletion increases the % of 
apoptotic cells [160]. In general, apoptosis is considered as a common mechanism of toxicity 
of various mycotoxins [68]. TCs induce apoptosis response via mitochondrial and non-
mitochondrial mechanisms [161]. The amphophilic nature of TCs facilitates their cytotoxic 
effect on cell membranes and inside the cell interact with ribosome and mitochondria 
causing inhibition of protein synthesis [162]. FB1 and OTA are able to induce apoptosis and 
necrosis in porcine kidney PK15 cells [163]. This is because the structure of FB1 resembles 
sphingoid bases which regulate cell growth, differentiation, transformation and apoptosis, 
and so it is not surprising that FB1 can alter growth of certain mammalian cells. The 
involvement of the TNF signal transduction pathway in FB1 induced apoptosis in African 
green monkey kidney fibroblasts has been shown [164]. Moreover, TNF-α production is 
responsible for FB1 induced apoptosis in mice primary hepatocytes [165]. Over expression 
of cytochrome P450-sensitized hepatocyte to TNFα-mediated cell death was associated with 
increased LPO and GSH depletion [166]. FB1 was reported to increase induction of 
cytochrome P450 isoforms and caused peroxidation of membrane lipids in isolated rat liver 
nuclei as well as GSH depletion of in pig kidney cells [167-169]. GSH depletion is known to 
activate c-Jun N-terminal kinase through redox inhibition of GST, which normally binds to 
and inhibits stress kinases [170]. Stimulation of apoptosis and necrosis in porcine granulosa 
cells by ZEA is dose-dependent manner via a caspase-3- and caspase-9-dependent 
mitochondrial pathway [171]. At the molecular level, fumonisins inhibit ceramide synthase 
and disrupt sphingolipid metabolism therefore influence apoptosis and mitosis [109]. The 
immunotoxic activity of OTA probably results from degenerative changes and cell death 
following necrosis and apoptosis in combination with slow replacement of affected immune 
cells due to inhibition of protein synthesis [85]. Moreover, PAT induce DNA damage and 
cell cycle arrest along with intrinsic pathway mediated apoptosis which may have dermal 
toxicological implications [172].  
Satratoxin H is thought to induce apoptosis of PC12 cells through the activation of p38 
mitogen activated protein kinase and c-Jun N-terminal kinase in GSH-sensitive manner 
[173]. Chemoprotective effects of flavonoid compounds against aflatoxins were confirmed in 
hens [174]. Moreover, cysteine and GSH has protective effect against PAT in the incident of 
rumen microbial ecosystem, however vitamin C and ferulic acid did not demonstrate an 
effect [175]. Metallothioneins (MTs) are four major isoforms found in cytoplasm, lysosomes, 
mitochondria and nuclei of mammalian cells [176]. MT-1 and 2 have ubiquitous tissue 
distribution particularly in liver, pancreas, intestine, and kidney, whereas MT-3 is found in 
brain and MT-4 in skin [177]. MT can play important role in the process of mycotoxins 
detoxification probably by redistribution of significant ions to transcriptional factors and 
interactions with oxygen radicals that may be generated by mycotoxins [23]. Nivalenol, a 
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trichothecene mycotoxin induces apoptosis in HL60 cells and that intracellular calcium ion 
plays a role in the nivalenol-induced secretion of IL-8 from this cell line [178]. 
6. Mycotoxins as therapeutics compound 
Cumulative knowledge about toxins structure and mechanism of action, as well as recent 
progress in the fields of cell biology, immunology, molecular biology and nanotechnology, 
enabled the development of different targeting strategies that are vital for converting a lethal 
toxin into a therapeutic agent. Fig. 9 showed three targeting strategies in toxin based therapy. 
i- Ligand targeted toxins upon administration to patients are internalized and intoxicate 
diseased cells, sparing healthy cells that do not display the target on their surface. ii- protease 
activated toxins: the toxin is engineered to be cleaved and activated by a disease-related 
intracellular or extracellular protease. Toxin cleavage may enhance cell-binding and/or 
translocation, stabilization or catalytic activity of the toxic moiety specifically in protease 
expressing cells, leading to their suppression. iii- toxin based suicide gene therapy: a DNA 
construct, encoding for a toxic polypeptide whose expression is regulated by a specific 
transcription regulation element, is delivered to a heterogeneous cell population [179].  
 
Figure 9. Three targeting strategies in toxin based therapy [179]. 
Because of their pharmacological activity, some mycotoxins or mycotoxin derivatives have 
found use as antibiotics, growth promoters, and other kinds of drugs. Ergocryptine is an 
ergot alkaloid that affects dopaminergic activity principally by interacting with D2-type 
receptors [180]. The bromation derivative has increased dopamine agonist activity, and is 
used against Parkinsonism and to reduce growth hormone secretion and milk production 
[181]. Ergotamine was among the most effective available agents for relieving migraine 
attacks [182]. Ergometrine and the semi-synthetic methylergometrine have been widely 
used for the prevention and treatment of excessive uterine bleeding following birth and also 
to initiate delivery [183]. Lysergic acid diethylamide is a serotonin receptor agonist [184] and 
can also interact with dopamine receptors to make it a useful tool for probing the 
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biochemical basis for behaviour [185]. Methysergide a semi-synthetic ergot alkaloid is a 
serotonin antagonist used in the treatment of migraine and is used for daily preventive 
therapy rather than in acute cases [184]. The TCs have been associated with various 
biological properties, such as antiviral especially as inhibitors of the replication of Herpes, 
antibiotic, antimalarial, antileukemic and immunotoxic [59,186]. Mycoestrogenic 
zearalenone is suspected to be a triggering factor for central precocious puberty 
development in girls. Due to its chemical resemblance to some anabolic agents used in 
animal breeding, ZEA may also represent a growth promoter in exposed patients [187]. 
Development of cyclosporine A as immunosuppressive drug has been traced back to the 
stimulus derived from the first highly-active cyclopeptides from Amantia mushrooms [188].  
7. Conclusion 
Mycotoxins are produced in a strain-specific way, and elicit some complicated and 
overlapping toxigenic activities in sensitive species that include carcinogenicity, inhibition of 
protein synthesis, immunosuppression, dermal irritation, and other metabolic perturbations. 
Mycotoxins usually enter the body via ingestion of contaminated foods, but inhalation of 
toxigenic spores and direct dermal contact are also important routes. There is sufficient 
evidence from animal models and human epidemiological data to conclude that mycotoxins 
pose an important danger to human and animal health. Trichothecenes cause protein 
synthesis inhibition via binding to the 18s rRNA of the ribosomal large subunit as a major 
mechanism underlying induction of cell apoptosis. T-2 toxin triggers a ribotoxic response 
through its high binding affinity to peptidyl transferase which is an integral part of the 60 s 
ribosomal subunit and interferes with the metabolism of membrane phospholipids and 
increases liver lipid peroxides. SH is thought to induce caspase-3 activation and apoptosis 
through the activation of MAPK and JNK in a GSH-sensitive manner. FB1-induced inhibition 
of ceramide synthesis can result in a wide spectrum of changes in lipid metabolism and 
associated lipid-dependent pathways. OTA has complex mechanisms of action that include 
mitochondrial impairment, formation of OTA-DNA adducts and induction of oxidative stress 
and apoptosis through caspase activation. Accordingly, the strict control of food quality, in 
both industrialized and developing countries, is therefore necessary to avoid mycotoxicosis. 
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